Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
naftidrofuryl benta
- Development stage
- Unknown
- Lead developer
- Benta Lyon
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Naftidrofuryl Benta is an approved generic formulation of naftidrofuryl (also known as nafronyl), developed and manufactured by Benta Lyon. It is indicated for the symptomatic treatment of intermittent claudication in patients with stage II chronic obstructive peripheral arterial disease (PAD). Naftidrofuryl acts as a selective antagonist of serotonin 5-HT2 receptors (specifically 5-HT2A, 5-HT2B, and 5-HT2C), thereby inhibiting serotonin-induced vasoconstriction, platelet aggregation, and vascular smooth muscle cell proliferation. Additionally, it enhances cellular aerobic metabolism by improving glucose and oxygen utilization, which helps maintain ATP levels in ischemic tissues.
- Brand names
- Naftidrofuryl BentaNaftiprax
02
Targets
HTR2A (Serotonin receptor 5-HT2A)HTR2B (5-Hydroxytryptamine Receptor 2B)HTR2C (5-hydroxytryptamine 2C receptor)
Beyond the preview
Go deeper on naftidrofuryl benta.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on naftidrofuryl benta.